Use of romiplostim for newly diagnosed immune thrombocytopenia in children

E. V. Suntsova; Сунцова Е. В.; I. I. Chikvina; Чиквина И. И.; M. N. Sadovskaya; Садовская М. Н.; N. N. Kotskaya; Коцкая Н. Н.; L. A. Hachatryan; Хачатрян Л. А.; D. D. Baydildina; Байдильдина Д. Д.; I. I. Kalinina; Калинина И. И.; U. N. Petrova; Петрова У. Н.; A. V. Pshonkin; Пшонкин А. В.; I. Ya. Lutfullin; Лутфуллин И. Я.; E. N. Lemazina; Лемазина Е. Н.; I. V. Osipova; Осипова И. В.; A. V. Galeeva; Галеева А. В.; O. S. Naumova; Наумова О. С.; I. V. Fisyn; Фисюн И. В.; G. V. Bikova; Быкова Г. В.; G. R. Kazaryan; Казарян Г. Р.; A. A. Maschan; Масчан А. А.; G. A. Novichkova; Новичкова Г. А.

doi:10.24287/1726-1708-2020-19-1-18-26

Use of romiplostim for newly diagnosed immune thrombocytopenia in children

Authors: Suntsova E.V.¹, Chikvina I.I.¹, Sadovskaya M.N.¹, Kotskaya N.N.¹, Hachatryan L.A.¹, Baydildina D.D.¹, Kalinina I.I.¹, Petrova U.N.¹, Pshonkin A.V.¹, Lutfullin I.Y.², Lemazina E.N.², Osipova I.V.², Galeeva A.V.², Naumova O.S.², Fisyn I.V.³, Bikova G.V.², Kazaryan G.R.², Maschan A.A.¹, Novichkova G.A.¹
Affiliations:
1. Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
2. Regional Children’s Hospital
3. Scientific and Clinical Multidisciplinary Center for Help for Mothers and Children named after Z.I. Kruglaya
Issue: Vol 19, No 1 (2020)
Pages: 18-26
Section: ORIGINAL ARTICLES
Submitted: 27.03.2020
Accepted: 27.03.2020
Published: 27.03.2020
URL: https://hemoncim.com/jour/article/view/302
DOI: https://doi.org/10.24287/1726-1708-2020-19-1-18-26
ID: 302

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Immune thrombocytopenia (ITP) is a disease with a heterogeneous clinical manifestation. In the majority of children newly diagnosed ITP is a self-limited benign disorder, while chronic ITP develops rarely. The clinical onset of ITP can occur in very different ways: from nearly invisible skin hemorrhage to severe life-threatening bleeding. Conventional treatments promote a response in most patients, but in a small number of children thrombocytopenia is unresponsive. In this article, we describe our experience of the clinical use of romiplostim in children with severe unresponsive newly diagnosed ITP. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The severity of bleeding decreased significantly after the start of romiplostim therapy in all cases. Durable complete (platelets > 100 × 109 /l) response was achieved in five out of six patients 4 to 8 weeks after starting therapy. Three children have remained in lasting remission for 1 to 3 years after the discontinuation of romiplostim. There were no adverse events associated with romiplostim.

Keywords

immune thrombocytopenia, romiplostim, children

About the authors

E. V. Suntsova

Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation

Author for correspondence.
Email: elena.suncova@fccho-moscow.ru
ORCID iD: 0000-0001-8404-1800

MD, Department of hematopoiesis depressions, myeloid leukemias, rare and inherited diseases,

117997, Moscow, Samory Mashela st., 1

Russian Federation

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register